Journal of Microencapsulation · 2023 · 10 citations · 18 references
PharmacyFood SciencePharmaceuticsDrug DeliveryOral Drug DeliveryPharmaceutical FormulationCoating TechnologyCoatingsDrug EncapsulationNasal FormulationsSuspension FormulationTaste MaskingGranulationMicroparticlesPolymeric MicrocapsulesPolymeric MicroparticlesTaste Masking CoatingsTaste-masked PowdersTaste-masked SuspensionsTaste-masking Agents
This research aims to develop bitter taste-masking microcapsules containing azithromycin (AZI) by a simpler and familiar method, fluid-bed coating technology, in comparison with Zithromax®. Cores of microcapsules, AZI microparticles, were prepared by fluid-bed granulation, then taste-masking polymer was covered on by fluid-bed coating technique. Eudragit L100, Eudragit RL100, and ethyl cellulose in single and combined with Eudragit L100 and Eudragit E100 were used as taste-masking polymers. The obtained microcapsules were characterised by taste-masking ability, in vitro release, SEM, coating thickness, and coating efficiency. Combination of ethyl cellulose and Eudragit E100 (3:1) in coating thickness of 45.13 ± 2.12% w/w prevents AZI release from microcapsules below bitter taste threshold (1.78 ± 1.17 µg/ml). Bioavailability of powders containing AZI microcapsules and pH modulators (50 mg Na3PO4 and 35 mg Mg(OH)2) was not significantly different from the reference product (Zithromax®, Pfizer, New York, NY) in the rabbit model (p > 0.05). These results support the possibility of developing a generic product containing AZI.
18
Sébastien G. Gouin · Trends in Food Science & Technology · 2004 · 1.3K citations
Milica Drašković, Djordje Medarević, Ivana Aleksić et al. · Drug Development and Industrial Pharmacy · 2016 · 49 citations · Full text
Martin J. Whitaker, S Spielmann, Dena Digweed et al. · The Journal of Clinical Endocrinology & Metabolism · 2015 · 47 citations · Full text
Pharmacy, Pediatrics, Pharmacology +14